Davide Prezzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Davide Prezzi has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Vicky Goh
School of Biomedical Engineering and Imaging Sciences, King’s College London, London, UK
17 shared publications - Flavia Neri
Department of Organ Failure and Transplantation, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy
7 shared publications L. Puviani
7 shared publicationsM. Tsivian
7 shared publicationsM. Pariali
6 shared publicationsR. Bertelli
6 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Elsevier in Medical Image Analysis
- Vol. 114, 104251
MambaX-Net: Dual-input Mamba-enhanced Cross-Attention network for longitudinal prostate MRI segmentation
- 17 August 2026
- Published by Elsevier in Medical Image Analysis
- Vol. 114, 104251
Open AccessMambaX-Net: Dual-input Mamba-enhanced Cross-Attention network for longitudinal prostate MRI segmentation
- Open Access
- 1 April 2025
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 29 (8) , 1-91
Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial
Background: Despite apparently curative treatment, many patients with colorectal cancer develop subsequent metastatic disease. Current prognostic models are criticised because they are based on standard staging and omit novel biomarkers. Improved prognostication is an unmet need. Objectives: To improve prognostication for colorectal cancer by developing a baseline multivariable model of standard clinicopathological predictors, and to then improve prediction via addition of promising novel imaging, genetic and immunohistochemical biomarkers. Design: Prospective multicentre cohort. Setting: Thirteen National Health Service hospitals. Participants: Consecutive adult patients with colorectal cancer. Interventions: Collection of prespecified standard clinicopathological variables and more novel imaging, genetic and immunohistochemical biomarkers, followed by 3-year follow-up to identify postoperative metastasis. Main outcome: Best multivariable prognostic model including perfusion computed tomography compared with tumour/node staging. Secondary outcomes: Additive benefit of perfusion computed tomography and other biomarkers to best baseline model comprising standard clinicopathological predictors; measurement variability between local and central review; biological relationships between perfusion computed tomography and pathology variables. Results: Between 2011 and 2016, 448 participants were recruited; 122 (27%) were withdrawn, leaving 326 (226 male, 100 female; mean ± standard deviation 66 ± 10.7 years); 183 (56%) had rectal cancer. Most cancers were locally advanced [≥ T3 stage, 227 (70%)]; 151 (46%) were node-positive (≥ N1 stage); 306 (94%) had surgery; 79 (24%) had neoadjuvant therapy. The resection margin was positive in 15 (5%); 93 (28%) had venous invasion; 125 (38%) had postoperative adjuvant chemotherapy; 81 (25%, 57 male) developed recurrent disease. Prediction of recurrent disease by the baseline clinicopathological time-to-event Weibull multivariable model (age, sex, tumour/node stage, tumour size and location, treatment, venous invasion) was superior to tumour/node staging: sensitivity: 0.57 (95% confidence interval 0.45 to 0.68), specificity 0.74 (95% confidence interval 0.68 to 0.79) versus sensitivity 0.56 (95% confidence interval 0.44 to 0.67), specificity 0.58 (95% confidence interval 0.51 to 0.64), respectively. Addition of perfusion computed tomography variables did not improve prediction significantly: c-statistic: 0.77 (95% confidence interval 0.71 to 0.83) versus 0.76 (95% confidence interval 0.70 to 0.82). Perfusion computed tomography parameters did not differ significantly between patients with and without recurrence (e.g. mean ± standard deviation blood flow of 60.3 ± 24.2 vs. 61.7 ± 34.2 ml/minute/100 ml). Furthermore, baseline model prediction was not improved significantly by the addition of any novel genetic or immunohistochemical biomarkers. We observed variation between local and central computed tomography measurements but neither improved model prediction significantly. We found no clear association between perfusion computed tomography variables and any immunohistochemical measurement or genetic expression. Limitations: The number of patients developing metastasis was lower than expected from historical data. Our findings should not be overinterpreted. While the baseline model was superior to tumour/node staging, any clinical utility needs definition in daily practice. Conclusions: A prognostic model of standard clinicopathological variables outperformed tumour/node staging, but novel biomarkers did not improve prediction significantly. Biomarkers that appear promising in small single-centre studies may contribute nothing substantial to prognostication when evaluated rigorously. Future work: It would be desirable for other researchers to externally evaluate the baseline model. Trial registration: This trial is registered as ISRCTN95037515. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 09/22/49) and is published in full in Health Technology Assessment; Vol. 29, No. 8. See the NIHR Funding and Awards website for further award information.
- 1 April 2025
- Published by National Institute for Health and Care Research in Health Technology Assessment
- Vol. 29 (8) , 1-91
Open AccessEvaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial
Background: Despite apparently curative treatment, many patients with colorectal cancer develop subsequent metastatic disease. Current prognostic models are criticised because they are based on standard staging and omit novel biomarkers. Improved prognostication is an unmet need. Objectives: To improve prognostication for colorectal cancer by developing a baseline multivariable model of standard clinicopathological predictors, and to then improve prediction via addition of promising novel imaging, genetic and immunohistochemical biomarkers. Design: Prospective multicentre cohort. Setting: Thirteen National Health Service hospitals. Participants: Consecutive adult patients with colorectal cancer. Interventions: Collection of prespecified standard clinicopathological variables and more novel imaging, genetic and immunohistochemical biomarkers, followed by 3-year follow-up to identify postoperative metastasis. Main outcome: Best multivariable prognostic model including perfusion computed tomography compared with tumour/node staging. Secondary outcomes: Additive benefit of perfusion computed tomography and other biomarkers to best baseline model comprising standard clinicopathological predictors; measurement variability between local and central review; biological relationships between perfusion computed tomography and pathology variables. Results: Between 2011 and 2016, 448 participants were recruited; 122 (27%) were withdrawn, leaving 326 (226 male, 100 female; mean ± standard deviation 66 ± 10.7 years); 183 (56%) had rectal cancer. Most cancers were locally advanced [≥ T3 stage, 227 (70%)]; 151 (46%) were node-positive (≥ N1 stage); 306 (94%) had surgery; 79 (24%) had neoadjuvant therapy. The resection margin was positive in 15 (5%); 93 (28%) had venous invasion; 125 (38%) had postoperative adjuvant chemotherapy; 81 (25%, 57 male) developed recurrent disease. Prediction of recurrent disease by the baseline clinicopathological time-to-event Weibull multivariable model (age, sex, tumour/node stage, tumour size and location, treatment, venous invasion) was superior to tumour/node staging: sensitivity: 0.57 (95% confidence interval 0.45 to 0.68), specificity 0.74 (95% confidence interval 0.68 to 0.79) versus sensitivity 0.56 (95% confidence interval 0.44 to 0.67), specificity 0.58 (95% confidence interval 0.51 to 0.64), respectively. Addition of perfusion computed tomography variables did not improve prediction significantly: c-statistic: 0.77 (95% confidence interval 0.71 to 0.83) versus 0.76 (95% confidence interval 0.70 to 0.82). Perfusion computed tomography parameters did not differ significantly between patients with and without recurrence (e.g. mean ± standard deviation blood flow of 60.3 ± 24.2 vs. 61.7 ± 34.2 ml/minute/100 ml). Furthermore, baseline model prediction was not improved significantly by the addition of any novel genetic or immunohistochemical biomarkers. We observed variation between local and central computed tomography measurements but neither improved model prediction significantly. We found no clear association between perfusion computed tomography variables and any immunohistochemical measurement or genetic expression. Limitations: The number of patients developing metastasis was lower than expected from historical data. Our findings should not be overinterpreted. While the baseline model was superior to tumour/node staging, any clinical utility needs definition in daily practice. Conclusions: A prognostic model of standard clinicopathological variables outperformed tumour/node staging, but novel biomarkers did not improve prediction significantly. Biomarkers that appear promising in small single-centre studies may contribute nothing substantial to prognostication when evaluated rigorously. Future work: It would be desirable for other researchers to externally evaluate the baseline model. Trial registration: This trial is registered as ISRCTN95037515. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 09/22/49) and is published in full in Health Technology Assessment; Vol. 29, No. 8. See the NIHR Funding and Awards website for further award information.
- Open Access
- 28 August 2023
- Published by Springer Nature in European Radiology
- Vol. 34 (2) , 1408
Correction: Diffusion-weighted imaging complements T2-weighted MRI for tumour response assessment in squamous anal carcinoma
- 28 August 2023
- Published by Springer Nature in European Radiology
- Vol. 34 (2) , 1408
Open AccessCorrection: Diffusion-weighted imaging complements T2-weighted MRI for tumour response assessment in squamous anal carcinoma
- Open Access
- 18 July 2023
- Published by Springer Nature in European Radiology
- Vol. 33 (11) , 7575-7584
Diffusion-weighted imaging complements T2-weighted MRI for tumour response assessment in squamous anal carcinoma
Objectives: A published tumour regression grade (TRG) score for squamous anal carcinoma treated with definitive chemoradiotherapy based on T2-weighted MRI yields a high proportion of indeterminate responses (TRG-3). We investigate whether the addition of diffusion-weighted imaging (DWI) improves tumour response assessment in the early post treatment period. Materials and methods: This retrospective observational study included squamous anal carcinoma patients undergoing MRI before and within 3 months of completing chemoradiotherapy from 2009 to 2020. Four independent radiologists (1–20 years’ experience) scored MRI studies using a 5-point TRG system (1 = complete response; 5 = no response) based on T2-weighted sequences alone, and then after a 12-week washout period, using a 5-point DWI-TRG system based on T2-weighted and DWI. Scoring confidence was recorded on a 5-point scale (1 = low; 5 = high) for each reading and compared using the Wilcoxon test. Indeterminate scores (TRG-3) from each reading session were compared using the McNemar test. Interobserver agreement was assessed using kappa statistics. Results: Eighty-five patients were included (mean age, 59 years ± 12 [SD]; 55 women). T2-weighted TRG-3 scores from all readers combined halved from 24% (82/340) to 12% (41/340) with DWI (p < 0.001). TRG-3 scores changed most frequently (41%, 34/82) to DWI-TRG-2 (excellent response). Complete tumour response was recorded clinically in 77/85 patients (91%). Scoring confidence increased using DWI (p < 0.001), with scores of 4 or 5 in 84% (287/340). Interobserver agreement remained fair to moderate (kappa range, 0.28–0.58). Conclusion: DWI complements T2-weighted MRI by reducing the number of indeterminate tumour responses (TRG-3). DWI increases radiologist’s scoring confidence. Clinical relevance statement: Diffusion-weighted imaging improves T2-weighted tumour response assessment in squamous anal cancer, halving the number of indeterminate responses in the early post treatment period, and increases radiologists’ confidence. Key Points: Tumour response based on T2-weighted MRI is often indeterminate in squamous anal carcinoma. Diffusion-weighted imaging alongside T2-weighted MRI halved indeterminate tumour regression grade scores assigned by four radiologists from 24 to 12%. Scoring confidence of expert and non-expert radiologists increased with the inclusion of diffusion-weighted imaging.
- 18 July 2023
- Published by Springer Nature in European Radiology
- Vol. 33 (11) , 7575-7584
Open AccessDiffusion-weighted imaging complements T2-weighted MRI for tumour response assessment in squamous anal carcinoma
Objectives: A published tumour regression grade (TRG) score for squamous anal carcinoma treated with definitive chemoradiotherapy based on T2-weighted MRI yields a high proportion of indeterminate responses (TRG-3). We investigate whether the addition of diffusion-weighted imaging (DWI) improves tumour response assessment in the early post treatment period. Materials and methods: This retrospective observational study included squamous anal carcinoma patients undergoing MRI before and within 3 months of completing chemoradiotherapy from 2009 to 2020. Four independent radiologists (1–20 years’ experience) scored MRI studies using a 5-point TRG system (1 = complete response; 5 = no response) based on T2-weighted sequences alone, and then after a 12-week washout period, using a 5-point DWI-TRG system based on T2-weighted and DWI. Scoring confidence was recorded on a 5-point scale (1 = low; 5 = high) for each reading and compared using the Wilcoxon test. Indeterminate scores (TRG-3) from each reading session were compared using the McNemar test. Interobserver agreement was assessed using kappa statistics. Results: Eighty-five patients were included (mean age, 59 years ± 12 [SD]; 55 women). T2-weighted TRG-3 scores from all readers combined halved from 24% (82/340) to 12% (41/340) with DWI (p < 0.001). TRG-3 scores changed most frequently (41%, 34/82) to DWI-TRG-2 (excellent response). Complete tumour response was recorded clinically in 77/85 patients (91%). Scoring confidence increased using DWI (p < 0.001), with scores of 4 or 5 in 84% (287/340). Interobserver agreement remained fair to moderate (kappa range, 0.28–0.58). Conclusion: DWI complements T2-weighted MRI by reducing the number of indeterminate tumour responses (TRG-3). DWI increases radiologist’s scoring confidence. Clinical relevance statement: Diffusion-weighted imaging improves T2-weighted tumour response assessment in squamous anal cancer, halving the number of indeterminate responses in the early post treatment period, and increases radiologists’ confidence. Key Points: Tumour response based on T2-weighted MRI is often indeterminate in squamous anal carcinoma. Diffusion-weighted imaging alongside T2-weighted MRI halved indeterminate tumour regression grade scores assigned by four radiologists from 24 to 12%. Scoring confidence of expert and non-expert radiologists increased with the inclusion of diffusion-weighted imaging.
- 14 February 2022
- Published by Springer Nature in Abdominal Radiology
- Vol. 47 (4) , 1414-1424
Bladder paragangliomas: a pictorial review
Bladder paragangliomas (bPGL) are rare neuroendocrine tumors arising from the sympathetic paraganglia present in the bladder wall. Bladder PGLs are typically submucosal or intramural but when subserosal may not be readily visible at cystoscopy. The average size at presentation is 3.9 cm (range 1.0–9.1 cm). When small, bPGL are usually spherical, well-marginated and homogeneous. Larger bPGL are typically more complex with peri- and intra-tumoral neovascularity and central necrosis. On ultrasound, increased color Doppler signal is typical. The increased soft tissue resolution of MRI enables localization of bPGL within the bladder wall more accurately than CT. Restricted diffusion and avid contrast enhancement help differentiate small bPGLs from leiomyomas, which have similar appearances on ultrasound and CT. Nuclear medicine techniques identify bPGLs and their metastases with high specificity, 68Ga-DOTATATE PET/CT having largely replaced 123I-mIBG SPECT/CT as the first line functional investigation. Imaging is essential to aid surgical planning, as endoscopic resection is often not possible or incomplete due to tumor location. For patients with advanced disease, 68Ga-DOTATATE PET/CT and 123I-mIBG SPECT/CT assess suitability for peptide receptor radionuclide therapy. Up to 63% of bPGL patients have a germline mutation, most commonly in the SDHB subunit gene, increasing their risk of developing pheochromocytomas and further paragangliomas; lifelong annual biochemical and periodic imaging screening from skull base to pelvis is therefore recommended. Graphical abstract
- 14 February 2022
- Published by Springer Nature in Abdominal Radiology
- Vol. 47 (4) , 1414-1424
Bladder paragangliomas: a pictorial review
Bladder paragangliomas (bPGL) are rare neuroendocrine tumors arising from the sympathetic paraganglia present in the bladder wall. Bladder PGLs are typically submucosal or intramural but when subserosal may not be readily visible at cystoscopy. The average size at presentation is 3.9 cm (range 1.0–9.1 cm). When small, bPGL are usually spherical, well-marginated and homogeneous. Larger bPGL are typically more complex with peri- and intra-tumoral neovascularity and central necrosis. On ultrasound, increased color Doppler signal is typical. The increased soft tissue resolution of MRI enables localization of bPGL within the bladder wall more accurately than CT. Restricted diffusion and avid contrast enhancement help differentiate small bPGLs from leiomyomas, which have similar appearances on ultrasound and CT. Nuclear medicine techniques identify bPGLs and their metastases with high specificity, 68Ga-DOTATATE PET/CT having largely replaced 123I-mIBG SPECT/CT as the first line functional investigation. Imaging is essential to aid surgical planning, as endoscopic resection is often not possible or incomplete due to tumor location. For patients with advanced disease, 68Ga-DOTATATE PET/CT and 123I-mIBG SPECT/CT assess suitability for peptide receptor radionuclide therapy. Up to 63% of bPGL patients have a germline mutation, most commonly in the SDHB subunit gene, increasing their risk of developing pheochromocytomas and further paragangliomas; lifelong annual biochemical and periodic imaging screening from skull base to pelvis is therefore recommended. Graphical abstract
- 1 August 2020
- Published by Elsevier in Seminars in Ultrasound, CT and MRI
- Vol. 41 (4) , 402-408
Multiparametric Ultrasound of Nonpalpable Focal Testicular Lesions
- 1 August 2020
- Published by Elsevier in Seminars in Ultrasound, CT and MRI
- Vol. 41 (4) , 402-408
Multiparametric Ultrasound of Nonpalpable Focal Testicular Lesions
- 1 August 2020
- Published by Elsevier in Seminars in Ultrasound, CT and MRI
- Vol. 41 (4) , 334-343
Multimodality Assessment of Cystic Renal Masses
- 1 August 2020
- Published by Elsevier in Seminars in Ultrasound, CT and MRI
- Vol. 41 (4) , 334-343
Multimodality Assessment of Cystic Renal Masses
- 1 June 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 295 (3) , 591-592
Predicting Growth Kinetics in Hereditary Renal Cancer with Diffusion-weighted MRI
- 1 June 2020
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 295 (3) , 591-592
Predicting Growth Kinetics in Hereditary Renal Cancer with Diffusion-weighted MRI
- Open Access
- 18 March 2019
- Published by Springer Nature in European Radiology
- Vol. 29 (10) , 5227-5235
Adaptive statistical iterative reconstruction (ASIR) affects CT radiomics quantification in primary colorectal cancer
Objectives To investigate whether adaptive statistical iterative reconstruction (ASIR), a hybrid iterative CT image reconstruction algorithm, affects radiomics feature quantification in primary colorectal cancer compared to filtered back projection. Additionally, to establish whether radiomics from single-slice analysis undergo greater change than those from multi-slice analysis. Methods Following review board approval, contrast-enhanced CT studies from 32 prospective primary colorectal cancer patients were reconstructed with 20% ASIR level increments, from 0 to 100%. Radiomics analysis was applied to single-slice and multi-slice regions of interest outlining the tumour: 70 features, including statistical (first-, second- and high-order) and fractal radiomics, were generated per dataset. The effect of ASIR was calculated by means of multilevel linear regression. Results Twenty-eight CT datasets were suitable for analysis. Incremental ASIR levels determined a significant change (p < 0.001) in most statistical radiomics features, best described by a simple linear relationship. First-order statistical features, including mean, standard deviation, skewness, kurtosis, energy and entropy, underwent a relatively small change in both single-slice and multi-slice analysis (median standardised effect size B = 0.08). Second-order statistical features, including grey-level co-occurrence and difference matrices, underwent a greater change in single-slice analysis (median B = 0.36) than in multi-slice analysis (median B = 0.13). Fractal features underwent a significant change only in single-slice analysis (median B = 0.49). Conclusions Incremental levels of ASIR affect significantly CT radiomics quantification in primary colorectal cancer. Second-order statistical and fractal features derived from single-slice analysis undergo greater change than those from multi-slice analysis. Key Points • Incremental levels of ASIR determine a significant change in most statistical (first-, second- and high-order) CT radiomics features measured in primary colorectal cancer, best described by a linear relationship. • First-order statistical features undergo a small change, both from single-slice and multi-slice radiomics analyses. • Most second-order statistical features undergo a greater change in single-slice analysis than in multi-slice analysis. Fractal features are only affected in single-slice analysis.
- 18 March 2019
- Published by Springer Nature in European Radiology
- Vol. 29 (10) , 5227-5235
Open AccessAdaptive statistical iterative reconstruction (ASIR) affects CT radiomics quantification in primary colorectal cancer
Objectives To investigate whether adaptive statistical iterative reconstruction (ASIR), a hybrid iterative CT image reconstruction algorithm, affects radiomics feature quantification in primary colorectal cancer compared to filtered back projection. Additionally, to establish whether radiomics from single-slice analysis undergo greater change than those from multi-slice analysis. Methods Following review board approval, contrast-enhanced CT studies from 32 prospective primary colorectal cancer patients were reconstructed with 20% ASIR level increments, from 0 to 100%. Radiomics analysis was applied to single-slice and multi-slice regions of interest outlining the tumour: 70 features, including statistical (first-, second- and high-order) and fractal radiomics, were generated per dataset. The effect of ASIR was calculated by means of multilevel linear regression. Results Twenty-eight CT datasets were suitable for analysis. Incremental ASIR levels determined a significant change (p < 0.001) in most statistical radiomics features, best described by a simple linear relationship. First-order statistical features, including mean, standard deviation, skewness, kurtosis, energy and entropy, underwent a relatively small change in both single-slice and multi-slice analysis (median standardised effect size B = 0.08). Second-order statistical features, including grey-level co-occurrence and difference matrices, underwent a greater change in single-slice analysis (median B = 0.36) than in multi-slice analysis (median B = 0.13). Fractal features underwent a significant change only in single-slice analysis (median B = 0.49). Conclusions Incremental levels of ASIR affect significantly CT radiomics quantification in primary colorectal cancer. Second-order statistical and fractal features derived from single-slice analysis undergo greater change than those from multi-slice analysis. Key Points • Incremental levels of ASIR determine a significant change in most statistical (first-, second- and high-order) CT radiomics features measured in primary colorectal cancer, best described by a linear relationship. • First-order statistical features undergo a small change, both from single-slice and multi-slice radiomics analyses. • Most second-order statistical features undergo a greater change in single-slice analysis than in multi-slice analysis. Fractal features are only affected in single-slice analysis.
- Open Access
- 3 July 2018
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 48 (1) , 13-26
Imaging biomarkers in oncology: Basics and application to MRI
Cancer remains a global killer alongside cardiovascular disease. A better understanding of cancer biology has transformed its management with an increasing emphasis on a personalized approach, so‐called “precision cancer medicine.” Imaging has a key role to play in the management of cancer patients. Imaging biomarkers that objectively inform on tumor biology, the tumor environment, and tumor changes in response to an intervention complement genomic and molecular diagnostics. In this review we describe the key principles for imaging biomarker development and discuss the current status with respect to magnetic resonance imaging (MRI).Level of Evidence: 5Technical Efficacy: Stage 5 J. Magn. Reson. Imaging 2018;48:13–26.
- 3 July 2018
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 48 (1) , 13-26
Open AccessImaging biomarkers in oncology: Basics and application to MRI
Cancer remains a global killer alongside cardiovascular disease. A better understanding of cancer biology has transformed its management with an increasing emphasis on a personalized approach, so‐called “precision cancer medicine.” Imaging has a key role to play in the management of cancer patients. Imaging biomarkers that objectively inform on tumor biology, the tumor environment, and tumor changes in response to an intervention complement genomic and molecular diagnostics. In this review we describe the key principles for imaging biomarker development and discuss the current status with respect to magnetic resonance imaging (MRI).Level of Evidence: 5Technical Efficacy: Stage 5 J. Magn. Reson. Imaging 2018;48:13–26.